[This review was originally posted at the Nieman Journalism Lab Synthroid No Rx, on April 22, 2011.]
Is Flipboard a competitor or collaborator?: Flipboard has quickly become one of the hottest news apps for the iPad, and it continued its streak last week when it announced it had raised $50 million in funding. Flipboard's Mike McCue told All Things Digital's Kara Swisher he'd be using the money to hire more staff and expand onto other devices, including the iPhone and Android platform. But he also talked to TechCrunch about using the money to fend off a rumored competitor in development at Google. (The Houston Chronicle's Dwight Silverman told Google not to bother, because Zite already does the trick for him.)
All this prompted a fantastic analysis of Flipboard from French media consultant Frederic Filloux, buying Synthroid online over the counter, who explained why Flipboard's distinctive user-directed blend of news media sites, RSS feeds, and social media is so wonderful for users but so threatening to publishers. Filloux argued that every media company should be afraid of Flipboard because they've built a superior news-consumption product for users, Where to buy Synthroid, and they're doing it on the backs of publishers. But none of those publishers can complain about Flipboard, because any of them could have (and should have) invented it themselves.
GigaOM's Mathew Ingram advised media companies to be willing to work with Flipboard for a similar "if you can't beat 'em, join 'em" reason: Its app has their apps beat in terms of customizability and usability, so they're better off trying to make money off of it than their own internal options, Synthroid No Rx. ReadWriteWeb's Dan Rowinski wrote about the possibility that Flipboard could be a better alternative partner for publishers than Apple, and Marshall Kirkpatrick wondered why publishers are up in arms about Flipboard in the first place.
Traditional media's personalized news move: One of the reasons that media companies might be less than willing to work with Flipboard is that some of them are building their own personalized news aggregation apps, two of which launched this week: The Washington Post Co.'s Trove and Betaworks' News.me, developed with the New York Times, buy Synthroid without prescription. INFOdocket's Gary Price has the best breakdown of what Trove does: It uses your Facebook account and in-app reading habits to give you personalized "channels" of news, determined by an algorithm and editors' picks — a bit of the "Pandora for news" idea, as the Post's Don Graham called it. (It's free, Synthroid steet value, so it's got that going for it, which is nice.)
All Things Digital's Peter Kafka suspected that Trove will be most useful on mobile media, as its web interface won't be much different from many people's current personalized home pages, and David Zax of Fast Company emphasized the social aspect of the service.
News.me is different from Trove in a number of ways Synthroid No Rx, : It costs 99 cents a week, and it's based not on your reading history, but on what other people on Twitter are reading. (Not just what they're tweeting, but what they're reading — Betaworks' John Borthwick called it reading "over other people's shoulders.") It also pays publishers based on the number of people who read their content through the app, Synthroid duration. That's part of the reason it's gotten the blessing of some media organizations that aren't typically aggregator friendly, like the Associated Press.
Since News.me is based so heavily on Twitter, it raises the obvious question of whether you'd be better off just getting your news for free from Twitter itself. Synthroid mg, That's what Business Insider's Ellis Hamburger wondered, and Gizmodo's Adrian Covert answered a definitive 'no,' though Martin Bryant of The Next Web said it could be helpful in stripping out the chatter of Twitter and adding an algorithmic aspect. GigaOM's Mathew Ingram looked at both services and concluded that they signal a willingness by some traditional media outlets to adjust their longtime broadcasting role to the modern model of the "Daily Me."
A good sign for the Times' pay plan: The overall news from the New York Times Co.'s quarterly earnings report this week wasn't good — net income is down 57% from a year ago — but there was one silver lining for online paid-content advocates: More than 100,000 people have begun paying for the Times' website since it began charging for access last month, Synthroid No Rx. (That number doesn't include those who got free subscriptions via Lincoln, but it does include those who are paying though cheaper introductory trials.)
As Advertising Age's Nat Ives pointed out, there's a lot that number doesn't tell us about traffic and revenue (particularly, where can i cheapest Synthroid online, as paidContent's Staci Kramer noted, how many people are paying full price for their subscriptions), but several folks, including Glynnis MacNicol of Business Insider, Low dose Synthroid, were surprised at how well the Times' pay plan is doing. (Its goal for the first year was 300,000 subscribers.) She said the figure compares favorably with the Financial Times, which got its 200,000th subscriber this year, nine years into its paywall, Synthroid canada, mexico, india.
Those numbers are particularly critical for the Times given the difficulty its company has had over the past several years — as Katie Feola of Adweek wrote, many analysts believe the pay plan is crucial for the Times' financial viability. "But this means the paper's future rests on an untested model that many experts believe can't work in the oversaturated news market," she wrote. "And the Times has to pray the ad market won’t decline faster than analysts predict."
A few other paid-content tidbits: Nine of Slovakia's largest news organizations put up a paywall together this week, and the pope is apparently pro-paywall, Synthroid use, too. At the Guardian, Cory Doctorow mused about how companies can (and can't) get people to pay for the content online in an age of piracy.
Google's hammer falls on eHow: When Google applied its algorithm adjustment last month Synthroid No Rx, to crack down on content farms, Demand Media's eHow actually came out better off (though others didn't fare so well, like the New York Times Co.'s About.com, as we found out this week). Google made a second round of updates last week, and eHow got nailed this time, losing 66% of their Googlejuice, Synthroid from mexico, according to Sistrix.
Search Engine Land's Matt McGee speculated that Google might have actually been surprised when eHow benefited the first time, and may have made this tweak in part as an effort to "correct" that. Demand Media, Synthroid treatment, meanwhile, called Sistrix's eHow numbers"significantly overstated," though the company's stock hit a new low on Monday. Mathew Ingram said investors have reason to worry, as Demand's success seems to be at the mercy of Google's every algorithm tweak.
A Pulitzer first: The Pulitzer Prizes were announced this week, and while the awards were spread pretty broadly among several news organizations, there were a couple of themes to note, Synthroid No Rx. As Felix Salmon and others pointed out, buy generic Synthroid, an abnormally large share of the awards went to business journalism, a trend the Columbia Journalism Review's Dean Starkman opined on in a bit more detail.
The biggest prize from a future-of-news perspective may have gone to ProPublica, whose series on some of the machinations that worsened the financial crisis was the first Pulitzer winner to never appear in print. Purchase Synthroid online, The Lab's Justin Ellis noted that other winners are including significant multimedia components, perhaps signaling a shift in the emphasis of one of journalism's most elite institutions. If you were wondering where WikiLeaks was in all this, well, the New York Times didn't submit its WikiLeaks-based coverage.
Reading roundup Synthroid No Rx, : No huge stories this week, but a few little things that are worth noting:
— Your weekly AOL/Huffington Post update: Jonathan Tasini came out swinging again regarding his lawsuit on behalf of unpaid HuffPo bloggers, Business Insider's Glynnis MacNicol responded in kind, Eric Snider told the story of getting axed from AOL's now-defunct Cinematical blog, and HuffPo unveiled features allowing readers to follow topics and writers.
— Missouri j-school students are chafing against requirements that they buy an iPad (they previously had to buy iPod Touches, canada, mexico, india, and they called that plan a bust). Meanwhile, Ben LaMothe of 10,000 Words had three ideas of social media skills that j-schools should teach.
— Two interesting data points on news innovation: A group led by Daniel Bachhuber put together some fascinating figures about and perspectives from Knight News Challenge grant recipients. And journalism researchers Seth Lewis and Tanja Aitamurto wrote at the Lab about news organizations using open API as a sort of external R&D department.
Similar posts: Order Armour. Glucophage Dosage. Lipitor Mg. Effects of Lipitor. Where can i order Retin A without prescription. Flagyl photos.
Trackbacks from: Synthroid No Rx. Synthroid No Rx. Synthroid No Rx. Synthroid pictures. Synthroid pics. Synthroid overnight.
[This review was originally posted at the Nieman Journalism Lab Glucophage No Rx, on March 4, 2011.]
Google's surgical strike against content farms: Two weeks after launching its site-blocking Chrome extension, Google made the central move in its fight against content farms by changing its algorithm to de-emphasize them in search results. The New York Times put the change in context, explaining the content farm phenomenon and its connection to Google. Search Engine Land's Danny Sullivan explained that Google is saying the changes only affect "scrapers" (sites that pull content from other sources), but that they're actually aimed at content farms, too. Glucophage trusted pharmacy reviews, And GigaOM's Mathew Ingram talked about why Google may be reluctant to publicly target content farms — because they run a lot of Google advertising.
A few early returns were good: TechCrunch approved of the change, and The Atlantic's Alexis Madrigal ran a test search comparing the old and new algorithms, finding that the information from the new one was "much, much better." Demand Media, the most prominent of the content farms, said it wasn't affected overall by the new formula, canada, mexico, india, though, as Henry Blodget of Business Insider noted, it's probably trying to wean itself off of Google reliance anyway.
In fact, it appears Demand Media may be telling the truth: Aaron Hall of SEO Book used Sistrix's data to point out that many of Demand Media's competitors were among the sites hardest hit by the change, while one of Demand's largest brands, eHow, actually got a boost. Hall implies that politics have played a role, and while there's nothing concrete suggesting that, the way the changes spared eHow does seem .., Glucophage No Rx. odd.
There's also bound to be plenty of collateral damage from the algorithmic shift, Glucophage recreational, and Wired looked at one Mac blog that's been nailed by the new formula (its Googlejuice was restored after Wired talked to Google about it). Danny Sullivan reported that Google hasn't made any significant changes to its new algorithm since rolling it out last week, though there are outlets to contact Google if you feel your site has been unfairly hurt.
Elsewhere in the conversation about search, The Columbia Journalism Review's Karen Stabiner gave an overview of the debate about search engine optimization: The anti-SEO crowd, led by the Washington Post's Gene Weingarten, worries that the SEO mindset will privilege the powerful and eventually kill off creativity in favor of numbingly literal language, taking Glucophage. Glucophage No Rx, The SEO evangelists, on the other hand, say it's just encouraging honesty and straightforwardness, something it's difficult to object to.
Facebook extends comments' reach: Facebook continued its integration with media content across the web this week with the launch of an updated comments system. Essentially, users can simultaneously post their comments on both a site and on Facebook, with subsequent comments under that thread posted to the site straight from Facebook. PBS MediaShift's Mark Glaser talked to Facebook's Justin Osofsky about the ins and outs of the new system, Online Glucophage without a prescription, and ReadWriteWeb noted that it has fewer features than the commenting update Facebook previewed last fall.
TechCrunch's Erick Schonfeld identified the two aspects of the updated system that will be most attractive to publishers. First, it requires commenters to use their real names, thus theoretically cutting down on trolls and spammers (this part, of course, has been available to publishers through Facebook commenting for a while), Glucophage No Rx. Second — and this is the new one — it extends the reach of a post, spreading into more Facebook news feeds and making it easier for more people to join in the conversation. This particularly excited Lehigh j-prof Jeremy Littau, who said it could create "a virtuous circle between community and content sharing."
There are downsides as well, and while media analyst Alan Mutter was optimistic about the social potential of the new system, he also pointed out that it will give Facebook even more information about its users, Glucophage pictures, which it won't be sharing with publishers. As GigaOM's Mathew Ingram noted, it's the same tradeoff publishers have been dealing with regarding Facebook for several years now: Does the value of tapping into Facebook's social potential outweigh the price of handing over commenting to a notoriously controlling company?
TBD's lessons — more startup, less ad reliance: TBD in its original form may have died last week, but the six-month-old Washington local news site continued to stimulate conversation this week. Where to buy Glucophage, Its station posted an ad for a new manager to head the site, and TBD's former manager, Jim Brady, talked with The Columbia Journalism Review about the site's model, framing the conflict there as not TV vs. web, but startup vs, Glucophage maximum dosage. legacy: Glucophage No Rx, "I think if we could do TBD with a pure startup mentality, and if we could fund it more with a V.C. or an angel kind of way, and if we didn’t have the legacy side to work with, then I think it would actually have a better chance to succeed."
Others posited similar reasons for TBD's demise: Web journalist Jane Stevens talked about a few causes centered on a lack of corporate commitment, and The Guardian's Emily Bell pinpointed TBD's inability to have its own ad sales team (an explanation with which Brady concurred). The debate over hyperlocal journalism, What is Glucophage, stirred by Alan Mutter last week, continued to simmer, with Robert Washburn of The Canadian Journalism Project defending it and Paul Gillin of Newspaper Death Watch saying we need to look at non-advertising-based business models for it, a point media consultant Dan Conover also made in more in-depth form at Xark.
Amid all the analyses of what went wrong at TBD, Mandy Jenkins, the social media manager there, buy Glucophage no prescription, took stock of what went right, noting four things other news orgs can take away from its tenure: organizational openness, self-promotion, opening info beyond the newsroom, and hiring for mindset over pedigree. Is Glucophage addictive, —
iPad, part deux: Apple made a few headlines by launching iPad 2, which is apparently kind of like the iPad, only it's the second edition. I'll entrust you to the care of Techmeme for all the details about the product itself and focus instead on what it means for publishers and the larger world of media, Glucophage No Rx. The Lab's Joshua Benton pointed out two implications in particular — the mounting evidence of an e-book explosion and the iPad's increasing usefulness for reporting.
Damon Kiesow of Poynter examined the latter point in some detail, looking at the iPad 2's specs from a content creation perspective, japan, craiglist, ebay, overseas, paypal. And Cory Bergman of Lost Remote looked at the device's increased video capability and predicted that it would help fuel a surge in multi-platform video consumption and production.
Elsewhere in mobile media, tech blogger John Gruber defended Apple's app subscription program by breaking down the arguments against it one by one. Glucophage No Rx, And in a smart counter to Gruber, the Lab's Joshua Benton said that while Apple obviously isn't a charity and the financial difficulties of publishers aren't its problem, the arrangement still isn't ideal. Both posts are among the sharpest takes on the issue I've read, so they're worth taking time to read through. Buy Glucophage from mexico, —
Reading roundup: What to read this weekend while firming up South by Southwest plans:
— In non-commenting Facebook news, Mashable's Vadim Lavrusik put together a great overview of the varied role of Facebook in journalism. And in non-Facebook commenting news, Los Angeles Times media reporter James Rainey made the case for requiring commenters to use their real names, while Mediaite's Alex Alvarez defended anonymous commenting, Glucophage from canadian pharmacy.
— Here at the Lab, Lois Beckett wrote two fascinating posts based on a talk by The New York Times' Gerry Marzorati — one on the future of long-form journalism, and the other on the Times' planned paywall. Two other thought-provoking pieces published here this week: One by Joshua Benton on language and viral content, and another by three data journalists on news organizations creating value out of the trust placed in them, Glucophage No Rx.
— Knight fellow Jeremy Adam Smith shared results from a survey on how meaningful journalism is being funded. It's a gold mine of statistics and information about the state of the journalism ecosystem.
— It's a pretty well-worn discussion, but Frederic Filloux's analysis of why incremental change isn't enough to rescue the newspaper industry is as succinct a summary of the current situation as I've seen. Even if you've heard it all, his piece is a good refresher.
Similar posts: Armour No Rx. Tramadol Dosage. Cephalexin For Sale. After Synthroid. Buy Bactrim from canada. Cheap Cipro.
Trackbacks from: Glucophage No Rx. Glucophage No Rx. Glucophage No Rx. Doses Glucophage work. Online buy Glucophage without a prescription. Glucophage long term.
[This review was originally posted at the Nieman Journalism Lab Bactrim Cost, on Feb. 4, 2011.]
Al Jazeera, the network, and social activism: For the last week, the eyes of the world have been riveted to the ongoing protests in Egypt, and not surprisingly, the news media themselves have been a big part of that story, Bactrim interactions, too. Many of them have been attacked by President Hosni Mubarak's lackeys, but the crisis has also been a breeding ground for innovative journalism techniques. Mashable put together a roundup of the ways journalists have used Twitter, Facebook, streaming video, Bactrim without a prescription, Tumblr, and Audioboo, and the Lab highlighted reporting efforts on Facebook, curation by Sulia, and explainers by Mother Jones. Google and Twitter also created Speak to Tweet to allow Egyptians cut off from the Internet to communicate.
But the organization that has shined the brightest over the past 10 days is unquestionably Al Jazeera, Bactrim Cost. The Qatar-based TV network has dominated web viewing, and has used web audio updates and Creative Commons to get information out quickly to as many people as possible, Bactrim long term.
Al Jazeera also faced stiff censorship efforts from the Egyptian government, which stripped its Egyptian license and shut down its Cairo bureau, then later stole some of its camera equipment. Through it all, the broadcaster kept up live coverage that online and offline, was considered the most comprehensive of any news organization. Low dose Bactrim, As Lost Remote's Cory Bergman pointed, Al Jazeera's coverage showed the continued power of compelling live video in a multimedia world.
Salon's Alex Pareene called Al Jazeera's coverage Bactrim Cost, an indictment on the U.S.' cable networks, and CUNY j-prof Jeff Jarvis and others urged cable companies to carry Al Jazeera English. Tech pioneer Doc Searls used the moment as a call for a more open form of cable TV: "The message cable should be getting is not just 'carry Al Jazeera,' but 'normalize to the Internet.' Open the pipes. Give us à la carte choices. Let us get and pay for what we want, not just what gets force-fed in bundles."
The protests also served as fresh fuel for an ongoing debate about the role of social media in social change and global political activism. Several critics — including Wired's David Kravets, Bactrim no rx, The New Yorker's Malcolm Gladwell, and SUNY Oswego prof Ulises Mejias— downplayed the role of social media tools such as Twitter in protests like Egypt's. Others, though, countered with a relatively unified theme: It's not really about the media tools per se, but about the decentralized, hyperconnected network in which they are bound up. J-profs Jeremy Littau and Robert Hernandez, along with GigaOM's Mathew Ingram, wrote the most thoughtful versions of this theme, and they're all worth checking out, Bactrim Cost.
Tepid reviews for The Daily: Within the bubble of media geeks, one story dominated the others this week: On Wednesday, Rupert Murdoch's News Corp. released The Daily, the first daily updated news publication produced specifically for the iPad. Bactrim photos, If you can't get enough coverage of The Daily, go check out Mediagazer's smorgasbord of links. I'll try to offer you a digestible (but still a bit overwhelming, I'll admit) summary of what people are saying about it.
Leading up to Wednesday's launch, Poynter's Damon Kiesow found many of the people who are working for the heretofore secretive publication, and media analyst Alan Mutter and All Things Digital's Peter Kafka examined the reasons why it might or might not take off. Bactrim Cost, Once the app was released Wednesday afternoon, the reviews came pouring in.
First, buy Bactrim online cod, the good: The first impressions of most of the digital experts polled by Poynter were positive, with several praising its visual design and one calling it "what I’ve always hoped newspapers would do with their tablet editions." PaidContent's Staci Cramer was generally complimentary, and The Guardian's Ian Betteridge gave it a (not terribly enthusiastic) "buy."
Most of the initial reviews, though, were not so kind. Much of the 'meh' was directed at lackluster content, Where can i find Bactrim online, as reviewer after reviewer expressed similar sentiments: "a general-interest publication that is not generally interesting" (The Columbia Journalism Review); "Murdoch’s reinvention of journalism looks a lot like the one before it" (Macworld); "fairly humdrum day-old stories that you might read in, well…a regular old printed newspaper" (Mathew Ingram); "little [of Murdoch's money], it appears, has been invested in editorial talent" (Mashable); "the Etch A Sketch edition of Us Magazine" (Alan Mutter); "barely brings digital journalism into the late 20th century, much less the 21st" (Mark Potts).
The bulk of that criticism seemed to be built on two foundational questions, asked by the Lab's Joshua Benton, which The Daily has apparently yet to answer convincingly: "Who is The Daily trying to reach, order Bactrim from mexican pharmacy. What problem is it trying to solve?" TechCrunch (and several of the above reviewers) asked similar questions, and GigaOM's Darrell Etherington attempted an answer, arguing that it's not for the obsessively-Twitter-checking news junkies, but iPad users struggling to adjust to life after newspapers.
A few other issues surrounding The Daily that drew attention: One was its separation from the web by virtue of its place within the proprietary iTunes Store and iPad, as well as the complete lack of links in or out, Bactrim Cost. (That hasn't stopped an authorized daily index of links to the web versions of articles from springing up, though.) Salon alum Scott Rosenberg and j-prof Dan Kennedy led the charge against the walled garden, Bactrim dosage, while the Lab's Megan Garber pointed out the draconian anti-aggregation language on The Daily's AP content, and Justin Ellis wondered how user engagement will work in that closed environment.
Then there were the economics of the publication: Media analyst Ken Doctor had two good sets of questions about what it will take for The Daily to financially succeed (the latter is more number-crunchy). Jeff Jarvis also looked at some possible numbers, and media consultant Amy Gahran chastised Murdoch for investing so much money in the venture. Gahran also looked at the hazards of dealing with Apple, and paidContent's Staci Kramer noted that Murdoch wants Apple to lower its share of the subscription revenue. Bactrim Cost, And on the News Corp. front, Bactrim alternatives, Slate's Jack Shafer wrote about the role Murdoch's impatience will play in its fate, and Subhub's Evan Radowski gave us a history lesson on News Corp. initiatives like this one.
Apple strikes against e-publishers: In its ongoing tightening of App Store access and regulations, Apple made a significant move this week by rejecting a Sony iPhone app that would have allowed users to buy e-books from the Sony Reader Store. GigaOM's Mathew Ingram did a great job of putting the decision in the context of Apple's past moves, No prescription Bactrim online, explaining why they make good business sense: "What’s the point of controlling a platform like the iPhone and the iPad if you can’t force people to pay you a carrying charge for hosting their content and connecting them with their customers?"
But others (even at GigaOM) were more skeptical. Jason Kincaid of TechCrunch said the decision underscores the downside of closed content platforms, and posited that it's the first shot in a war between Apple and Amazon's Kindle, and Slate's Farhad Manjoo urged Amazon to pull its Kindle app out of the App Store. In another widely expected move along the same lines, Apple also told publishers that within two months, any app that doesn't take payments through its iTunes Store would be rejected, Bactrim Cost.
AOL follows Demand's content-farming path: We talked last week about Demand Media's explosive IPO and Google's intention to make content farms harder to find in searches, and we have a couple of updates to those issues this week. First, Seamus McCauley of Virtual Economics explained why he's skeptical about Demand's true valuation, not to mention its accounting methods, doses Bactrim work. And while Google's algorithm limiting content farms is not yet live, search engine startup Blekko has banned many content farm domains, including Demand's eHow, from its search results. Meanwhile, the debate over Demand continued, Buy no prescription Bactrim online, with Adotas' Gavin Dunaway and MinnPost's John Reinan delivering this week's broadsides against the company. Bactrim Cost, AOL hasn't been talked about as a content farm too much as of yet, but that may change after Business Insider's publication this week of a leaked internal document called "The AOL Way," which reads a lot like the textbook content farm strategy guide. GigaOM's Mathew Ingram and Fortune's Dan Mitchell blasted the plan, with Ingram asserting that "the chasing of eyeballs and pageviews is a game of constantly diminishing returns." Martin Bryant of The Next Web, on the other hand, said AOL's model is not a misguided, diabolical plan, but "an inevitable, turbo-powered evolution of what’s happened in the media industry for many years."
Reading roundup: A few things to check out this weekend while you're most likely snowed in somewhere:
— This week's WikiLeaks update: Julian Assange sat down with 60 Minutes for an interview (there's also a video on what it took to make that happen), buy cheap Bactrim, WikiLeaks was nominated for the Nobel Peace Prize, The Guardian's Alan Rusbridger gave his own account about working with WikiLeaks, and NYU's Adam Penenberg made the case for Assange as a journalist. Reuters also profiled the new WikiLeaks spinoff OpenLeaks.
— A few paid-content notes: The New York Times isn't releasing details of its paywall plan just yet, but it is fixing technological glitches with the system right now, while Media Week reported that some industry analysts are skeptical of its chances. Meanwhile, the Philadelphia Inquirer and Daily News announced they'll start offering an e-edition to paying subscribers.
— GigaOM founder Om Malik wrote a simple but insightful guide to creating a successful consumer Internet service, focusing on three elements: A clear purpose, ease of use, and fun.
— Harvard prof David Weinberger has a short, thought-provoking post offering a 21st-century update on Marshall McLuhan's famous "The medium is the message" aphorism: "We are the medium." It's a simple idea, but it has some potentially profound implications, a few of which Weinberger begins to flesh out.
Similar posts: Bactrim Dosage. Zoloft Cost. Bactrim Price. Cipro no prescription. Taking Retin A. Order Flagyl from mexican pharmacy.
Trackbacks from: Bactrim Cost. Bactrim Cost. Bactrim Cost. Purchase Bactrim online no prescription. Bactrim australia, uk, us, usa. Where can i find Bactrim online.
[This review was originally posted at the Nieman Journalism Lab Armour For Sale, on Jan. 28, 2011.]
Playing WikiLeaks Whack-a-Mole: Ever since WikiLeaks broke through into the public's consciousness last summer, observers have been predicting that its functions would be replicated by other organizations, both within and outside traditional journalism. We've seen signs of that for a couple of months, but the movement toward leakiness got a few big boosts this week with the launch of a leak submission system by Al Jazeera and the news that The New York Times is considering one of its own, Armour gel, ointment, cream, pill, spray, continuous-release, extended-release.
Al Jazeera started off with the release of the Palestine Papers, and the Palestinian Authority responded by blocking the new site. The Times' executive editor, Bill Keller, said his paper's looking at something along the lines of Al Jazeera's system, Cheap Armour, and a group from the CUNY Graduate School is also launching Localeaks, which allows leakers to submit leaks to any one of more than 1,400 local newspapers in the U.S. Meanwhile, WikiLeaks' Julian Assange told the Associated Press that he's up to 20 media partners and is hoping to triple that number in the next few months, Armour For Sale.
A couple of writers weighed in with thoughtful takes on these developments: Mathew Ingram of GigaOM suggested that leakers might still prefer WikiLeaks because it allows them freedom from relying on only one organization's view of the documents, since WikiLeaks works with numerous competing news outlets. In a particularly insightful piece, Raffa Khatchadourian of The New Yorker expounded on the strengths and weaknesses of the traditional media alternative to WikiLeaks, buy cheap Armour no rx, focusing on the two organizations' ties to societal conventions: "accountability limits the Times, but it also offers it protections—protections that WikiLeaks at the moment does not enjoy because, among other things, there is not enough public consensus on what it is and stands for."
That chasm between the culture of the Times and WikiLeaks was vividly manifested this week with the Times' publication of an essay by Keller about his paper's dealings with WikiLeaks, painting a less-than-flattering picture of Assange. Order Armour online overnight delivery no prescription, (The Daily Beast and Yahoo News have good summaries of the piece.) WikiLeaks denounced the article, and Gawker's John Cook found Keller's insults off-putting, especially given the service Assange has done his paper. Cook also pointed out the degree to which the Times worked with the U.S. Armour For Sale, State Department in releasing the cables, a practice that's probably quite at odds with Assange's theory of radical transparency.
Ongo's paid aggregation plan: Few topics are hotter in the future-of-news world than aggregation, except perhaps for the ongoing quest to find a way to make money off of news online. So when a startup combines both, Armour class, like Ongo is doing, people are going to pay attention. The service, launched this week by eBay/Skype/PayPal alum Alex Kazim, offers aggregated news from several major news outlets for fees starting at $6.99 a month. Armour from canada, Kazim told paidContent that he's targeting users who graze among numerous news sites and value a sharp user experience more highly than the content itself.
The instant reviews weren't exactly enthusiastic, Armour For Sale. Mashable's Lauren Indvik said that Ongo's slim selection of news outlets will likely leave users getting only a fraction of their daily news via Ongo — something they may not be willing to pay for. (Andrew Edgecliffe-Johnson of the Financial Times made a similar argument.) Zee Kane of The Next Web said Flipboard, Feedly and Google Reader all provide similar services, and they're all cheaper and better. Lost Remote's Cory Bergman compared Ongo with Hulu's model, but noted that Hulu's product (entertainment TV) is scarcer and more highly demanded than Ongo's product (online news), Armour mg.
GigaOM's Mathew Ingram had the harshest criticism, arguing that no one who knows how to use RSS will have any reason to use Ongo."Ongo seems like yet another Hail Mary pass aimed at trying to rewind the clock and impose scarcity on media content, and one that will likely fail just as quickly as others have," he wrote. Armour For Sale, But there is one group of people who have quite a bit of faith in Ongo — newspaper executives, particularly those from The New York Times, The Washington Post, and Gannett, all of whom have invested in the company. The Times, Armour pics, of course, is planning an online paid-content plan of its own, which The Wall Street Journal reported it will begin rolling out next month. According to the Journal, the Times' current plan has an iPad/web bundle costing more than twice as much as a website subscription alone, leading Reuters' Felix Salmon to wonder why the Times seems to be planning on pushing readers away from its iPad app.
Wall Street's warm welcome for Demand Media: Demand Media, cheap Armour no rx, the most prominent of the "content farms" that have drawn so much criticism over the past year or so, had an extraordinarily successful initial public offering on Wall Street this week, with first-day trading pushing its valuation to $1.5 billion Wednesday — higher than The New York Times Co. itself. That had to sting quite a bit for the Times, especially considering that, as Rafat Ali reported and The Wall Street Journal confirmed, the Times had almost bought Demand a few years back, Armour For Sale.
Demand's trading was driven by a lot of enthusiasm — exemplified by Keith Richman at Advertising Age — about the efficiency and profitability of its business model, Kjøpe Armour på nett, köpa Armour online, but its detractors are still loud, too. Forbes' Jeff Bercovici mocked some ridiculous Demand articles, and The Columbia Journalism Review's Lauren Kirchner told journalists why they should care: Demand is "a company that works every day to lower the standards of online content, that devalues the skills of reporting and writing, and that removes any incentive for original thought in exchange for quantity and speed."
Someone else who signaled its displeasure with companies like Demand this week: Google, on whom much of Demand's business model rests, Armour class. In a blog post, Google's Matt Cutts explained the shift in the company's antispam efforts toward a content-farm crackdown. Lauren Kirchner called spammers "tapeworms" for Google, but at Business Insider, Ben Elowitz argued that Google and Demand have a mutual (and mutually destructive) advertising-based relationship. Armour For Sale, Demand's Richard Rosenblatt, meanwhile, insisted that Cutts' post wasn't about Demand, and that the two companies have a healthy, "synergistic" relationship. Where can i buy cheapest Armour online, Search Engine Land's Danny Sullivan imagined what a Demand Media edition of The New York Times' website might look like, then urged news companies to both news coverage and "answers coverage" like the content farms — only a bit smarter.
Olbermann's exit: When MSNBC pundit Keith Olbermann ended his eight-year run hosting Countdown on Friday, it wasn't entirely unexpected — MSNBC suspended Olbermann in November for his contributions to Democratic candidates, touching off a simmering debate about objectivity and journalism. As The New York Times reported, Olbermann's exit was weeks in the making, Armour over the counter. Though its exact cause wasn't clear, Yahoo's Michael Calderone threw out a few possible reasons why Olbermann might have left.
In the wake of his departure, there was a bit of talk about Olbermann's place within the past decade of journalism: Lehigh j-prof Jeremy Littau said Olbermann's angry voice didn't fit the times anymore, though the Philadelphia Daily News' Will Bunch made a similar point in a more positive vein, suggesting Olbermann left because he had accomplished his mission giving voice to the appalled journalist and citizen, Armour For Sale. And Dave Winer urged Olbermann to now go directly to his audience, using the web to circumvent the traditional he just left.
Apple's subscription struggle: Apple's clampdown on publishers' hopes for subscriptions for the iPhone and iPad continues to ripple through the media world. Buy cheap Armour no rx, French analyst Frederic Filloux has a fantastic breakdown of the situation, explaining why publishers (especially smaller ones) are so upset and why they could take their app development elsewhere. ReadWriteWeb's Richard MacManus said the subscription plans would be good for consumers and publishers, but cautioned that it would put much of the business under Apple's control.
A few individual publishers' iPad developments: PaidContent gave us details of The Guardian's evolving plans Armour For Sale, for an iPad app, new publisher Nomad Editions launched four tablet-only magazines, and oh yeah, apparently Rupert Murdoch's coming out with some daily tablet-based news publication next week.
Reading roundup: A lot of big stories this week, so I'll go light on the ephemera:
— Last week's conversation (summarized nicely by David Cohn) about journalism education spilled over into this week. Tech pioneer Dave Winer provided this week's big idea with a great post on educating the "journo-programmer" (published in condensed form at the Lab), buy Armour online cod. Among his ideas: Teach aggregation, get away from the hackathon model, and just start doing it. PBS MediaShift profiled a innovative journalism program with which Winer is affiliated — Jay Rosen's Studio 20 at NYU.
— Your deep thought on the web for the week: Tech luminary John Battelle on the need for a new, revealed identity online.
— On the media literacy front, Paul Bradshaw, a j-prof at City University London and Birmingham City University, wrote a fantastic guide to verifying information online, focusing on content, context, and code.
— And in case you were wondering just what the heck is going on with the web right now, uh, The Oatmeal has you more than covered.
Similar posts: Synthroid Price. Order Tramadol. Retin A Cost. Retin A from mexico. Armour no prescription. Lipitor maximum dosage.
Trackbacks from: Armour For Sale. Armour For Sale. Armour For Sale. Armour schedule. Purchase Armour online. After Armour.
[This review was originally posted at the Nieman Journalism Lab Flagyl Dosage, on July 30, 2010.]
WikiLeaks, data journalism and radical transparency: I'll be covering two weeks in this review because of the Lab's time off last week, but there really was only one story this week: WikiLeaks' release of The War Logs, a set of 90,000 documents on the war in Afghanistan. There are about 32 angles to this story and I'll try to hit most of them, but if you're pressed for time, the essential reads on the situation are Steve Myers, C.W. Anderson, Clint Hendler and Janine Wedel and Linda Keenan.
WikiLeaks released the documents on its site on Sunday, cooperating with three news organizations — The New York Times, The Guardian and Der Spiegel — to allow them to produce special reports on the documents as they were released. The Nation's Greg Mitchell ably rounded up commentary on the documents' political implications (one tidbit from the documents for newsies: Evidence of the U.S. military paying Afghan journalists to write favorable stories), order Flagyl from mexican pharmacy, as the White House slammed the leaks and the Times for running them, and the Times defended its decision in the press and to its readers.
The comparison that immediately came to many people's minds was the publication of the Pentagon Papers on the Vietnam War in 1971, and two Washington Post articles examined the connection, Flagyl Dosage. (The Wall Street Journal took a look at both cases' First Amendment angles, too.) But several people, most notably ProPublica's Richard Tofel and Slate's Fred Kaplan, quickly countered that the War Logs don't come close to the Pentagon Papers' historical impact. Flagyl pics, They led a collective yawn that emerged from numerous political observers after the documents' publication, with ho-hums coming from Foreign Policy, Mother Jones, the Washington Post, and even the op-ed page of the Times itself. Slate media critic Jack Shafer suggested ways WikiLeaks could have planned its leak better to avoid such ennui.
But plenty of other folks found a lot that was interesting about the entire situation. Flagyl Dosage, (That, of course, is why I'm writing about it.) The Columbia Journalism Review's Joel Meares argued that the military pundits dismissing the War Logs as old news are forgetting that this information is still putting an often-forgotten war back squarely in the public's consciousness. But the most fascinating angle of this story to many of us future-of-news nerds was that this leak represents the entry of an entirely new kind of editorial process into mainstream news, Flagyl description. That's what the Atlantic's Alexis Madrigal sensed early on, and several others sussed out as the week moved along. The Times' David Carr called WikiLeaks' quasi-publisher role both a new kind of hybrid journalism and an affirmation of the need for traditional reporting to provide context. Poynter's Steve Myers made some astute observations about this new kind of journalism, including the rise of the source advocate and WikiLeaks' trading information for credibility. NYU j-prof Jay Rosen noted thatWikiLeaks is the first "stateless news organization," able to shed light on the secrets of the powerful because of freedom provided not by law, but by the web.
Both John McQuaid and Slate's Anne Applebaum emphasized the need for data to be, as McQuaid put it, "marshaled in service to a story, an argument," with McQuaid citing that as reason for excitement about journalism and Applebaum calling it a case for traditional reporting, Flagyl Dosage. Here at the Lab, Low dose Flagyl, CUNY j-prof C.W. Anderson put a lot this discussion into perspective with two perceptive postson WikiLeaks as the coming-out party for data journalism. He described its value well: "In these recent stories, its not the presence of something new, but the ability to tease a pattern out of a lot of little things we already know that’s the big deal."
As for WikiLeaks itself, the Columbia Journalism Review's Clint Hendler provided a fascinating account of how its scoop ended up in three of the world's major newspapers, including differences in WikiLeaks' and the papers' characterization of WikiLeaks' involvement, which might help explain its public post-publication falling-out with the Times, Flagyl over the counter. The Times profiled WikiLeaks and its enigmatic founder, Julian Assange, and several others trained their criticism on WikiLeaks itself — specifically, on the group's insistence on radical transparency from others but extreme secrecy from itself. The Washington Post's Howard Kurtz said WikiLeaks is "a global power unto itself Flagyl Dosage, ," not subject to any checks and balances, and former military reporter Jamie McIntyre called WikiLeaks "anti-privacy terrorists."
Several others were skeptical of Assange's motives and secrecy, and Slate's Farhad Manjoo wondered how we could square public trust with such a commitment to anonymity. In a smart Huffington Post analysis of that issue, Janine Wedel and Linda Keenan presented this new type of news organization as a natural consequence of the new cultural architecture (the "adhocracy, Buy Flagyl from mexico, " as they call it) of the web: "These technologies lend themselves to new forms of power and influence that are neither bureaucratic nor centralized in traditional ways, nor are they generally responsive to traditional means of accountability."
Keeping readers out with a paywall: The Times and Sunday Times of London put up their online paywall earlier this month, the first of Rupert Murdoch's newspapers to set off on his paid-content mission (though some other properties, like The Wall Street Journal, have long charged for online access). Last week, we got some preliminary figures indicating how life behind the wall is going so far: Former Times media reporter Dan Sabbagh said that 150,000 of the Times' online readers (12 percent of its pre-wall visitors) had registered for free trials during the paywall's first two weeks, discount Flagyl, with 15,000 signing on as paying subscribers and 12,500 subscribing to the iPad app. PaidContent also noted that the Times' overall web traffic is down about 67 percent, adding that the Times will probably tout these types of numbers as a success.
The Guardian did its own math and found that the Times' online readership is actually down about 90 percent — exactly in line with what the paper's leaders and industry analysts were expecting. Everyone noted that this is exactly what Murdoch and the Times wanted out of their paywall — to cut down on drive-by readers and wring more revenue out of the core of loyal ones, Flagyl Dosage. Online buying Flagyl hcl, GigaOM's Mathew Ingram explained that rationale well, then ripped it apart, calling it "fundamentally a resignation from the open web" because it keeps readers from sharing (or marketing) it with others. SEOmoz's Tom Critchlow looked at the Times' paywall interface and gave it a tepid review.
Meanwhile, another British newspaper that charges for online access, the Financial Times, is boasting strong growth in online revenue, where to buy Flagyl. The FT's CEO, John Ridding, credited the paper's metered paid-content system and offered a moral argument for paid access online, drawing on Time founder Henry Luce's idea that an exclusively advertising-reliant model weakens the bond between a publication and its readers.
Flipboard and the future of mobile media Flagyl Dosage, : In just four months, we've already seen quite a few attention-grabbing iPad apps, but probably none have gotten techies' hearts racing quite like Flipboard, which was launched last week amid an ocean of hype. As Mashable explained, Flipboard combines social media and news sources of the user's choosing to create what's essentially a socially edited magazine for the iPad. Flagyl photos, The app got rave reviews from tech titans like Robert Scoble and ReadWriteWeb, which helped build up enough demand that it spent most of its first few post-release days crashed from being over capacity.
Jen McFadden marveled at Flipboard's potential for mobile advertising, given its ability to merge the rich advertising experience of the iPad with the targeted advertising possibilities through social media, though Martin Belam wondered whether the app might end up being "yet another layer of disintermediation that took away some of my abilities to understand how and when my content was being used, or to monetise my work." Tech pioneer Dave Winer saw Flipboard as one half of a brilliant innovation for mobile media and challenged Flipboard to encourage developers to create the other half.
At the tech blog Gizmodo, Joel Johnson broke in to ask a pertinent question: Is Flipboard legal, Flagyl maximum dosage. The app scrapes content directly from other sites, rather than through RSS, like the Pulse Reader, Flagyl Dosage. Flipboard's defense is that it only offers previews (if you want to read the whole thing, you have to click on "Read on Web"), but Johnson delved into some of the less black-and-white scenarios and legal issues, too. (Flipboard, for example, Buy generic Flagyl, takes full images, and though it is free for now, its executives plan to sell their own ads around the content under revenue-sharing agreements.) Stowe Boyd took those questions a step further and looked at possible challenges down the road from social media providers like Facebook.
A new perspective on content farms: Few people had heard of the term "content farms" about a year ago, but by now there are few issues that get blood boiling in future-of-journalism circles quite like that one. PBS MediaShift's eight-part series on content farms, published starting last week, is an ideal resource to catch you up on what those companies are, is Flagyl addictive, why people are so worked up about them, and what they might mean for journalism. Flagyl Dosage, (MediaShift defines "content farm" as a company that produces online content on a massive scale; I, like Jay Rosen, would define it more narrowly, based on algorithm- and revenue-driven editing.)
The series includes an overview of some of the major players on the online content scene, pictures of what writing for and training at a content farm is like, and two posts on the world of large-scale hyperlocal news. It also features an interesting defense of content farms by Dorian Benkoil, who argues that large-scale online content creators are merely disrupting an inefficient, expensive industry (traditional media) that was ripe for a kick in the pants.
Demand Media's Jeremy Reed responded to the series with a note to the company's writers that "You are not a nameless, Buying Flagyl online over the counter, faceless, soul-less group of people on a 'farm.' We are not a robotic organization that’s only concerned about numbers and data. We are a media company. We work together to tell stories," and Yahoo Media's Jimmy Pitaro defended the algorithm-as-editor model in an interview with Forbes. Outspoken content-farm critic Jason Fry softened his views, too, urging news organizations to learn from their algorithm-driven approach and let their audiences play a greater role in determining their coverage, Flagyl Dosage.
Reading roundup: A few developments and ideas to take a look at before the weekend:
— We've written about the FTC's upcoming report on journalism and public policy earlier this summer, and Google added its own comments to the public record last week, urging the FTC to move away from "protectionist barriers." Google-watcher Jeff Jarvis gave the statement a hearty amen, and the Boston Globe's Jeff Jacoby chimed in against a government subsidy for journalism.
— Former equity analyst Henry Blodget celebrated The Business Insider's third birthday with a very pessimistic forecast of The New York Times' future, and, by extension, the traditional media's as well. Meanwhile, Judy Sims targeted a failure to focus on ROI as a cause of newspapers' demise.
— The Columbia Journalism Review devoted a feature to the rise of private news, in which news organizations are devoted to a niche topic for an intentionally limited audience.
Similar posts: Cephalexin Price. Glucophage For Sale. Cephalexin Dosage. Herbal Tramadol. Cephalexin interactions. Cephalexin overnight.
Trackbacks from: Flagyl Dosage. Flagyl Dosage. Flagyl Dosage. Where can i buy Flagyl online. Flagyl dangers. Comprar en línea Flagyl, comprar Flagyl baratos.